2001年欧美相继公布慢性心力衰竭(心衰)诊治指南,制定了以血管紧张素转换酶抑制剂(ACEI)和β受体阻滞剂为基石的规范治疗策略。然而,由于这些药物在临床应用中存在一定难度,至今仍然远远没有达到临床研究中所能耐受的使用率和剂量,许多患者因此没有获得这些药物治疗预期带来的? 2001 Europe and the United States have announced the diagnosis and treatment of chronic heart failure (heart failure) guidelines, the development of angiotensin-converting enzyme inhibitors (ACEI) and β-blockers as the cornerstone of normative treatment strategy. However, due to the difficulty in clinical application of these drugs, the use rates and doses that can not be tolerated in clinical studies are still far from enough. Therefore, many patients are not expected to receive these drug treatments.